SI1855677T1 - 3,11 b-cis-dihidrotetrabenazin za zdravljenje shizofrenije in drugih psihoz - Google Patents

3,11 b-cis-dihidrotetrabenazin za zdravljenje shizofrenije in drugih psihoz

Info

Publication number
SI1855677T1
SI1855677T1 SI200630210T SI200630210T SI1855677T1 SI 1855677 T1 SI1855677 T1 SI 1855677T1 SI 200630210 T SI200630210 T SI 200630210T SI 200630210 T SI200630210 T SI 200630210T SI 1855677 T1 SI1855677 T1 SI 1855677T1
Authority
SI
Slovenia
Prior art keywords
psychoses
schizophrenia
cis
treatment
dihydrotetrabanezine
Prior art date
Application number
SI200630210T
Other languages
English (en)
Slovenian (sl)
Inventor
Andrew John Duffield
Jean Elisabeth Yarrow
Original Assignee
Cambridge Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by Cambridge Lab Ireland Ltd filed Critical Cambridge Lab Ireland Ltd
Publication of SI1855677T1 publication Critical patent/SI1855677T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200630210T 2005-08-06 2006-08-04 3,11 b-cis-dihidrotetrabenazin za zdravljenje shizofrenije in drugih psihoz SI1855677T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds
EP06765238A EP1855677B1 (en) 2005-08-06 2006-08-04 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Publications (1)

Publication Number Publication Date
SI1855677T1 true SI1855677T1 (sl) 2009-04-30

Family

ID=37400949

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630210T SI1855677T1 (sl) 2005-08-06 2006-08-04 3,11 b-cis-dihidrotetrabenazin za zdravljenje shizofrenije in drugih psihoz

Country Status (20)

Country Link
US (1) US20110257220A1 (cg-RX-API-DMAC7.html)
EP (2) EP1855677B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009504622A (cg-RX-API-DMAC7.html)
KR (1) KR20080033500A (cg-RX-API-DMAC7.html)
AT (2) ATE415968T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006277753B2 (cg-RX-API-DMAC7.html)
CA (1) CA2620960A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108843T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006004009D1 (cg-RX-API-DMAC7.html)
DK (1) DK1855677T3 (cg-RX-API-DMAC7.html)
ES (1) ES2318771T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20090074T3 (cg-RX-API-DMAC7.html)
MX (1) MX2008001549A (cg-RX-API-DMAC7.html)
NZ (1) NZ566011A (cg-RX-API-DMAC7.html)
PL (1) PL1855677T3 (cg-RX-API-DMAC7.html)
PT (1) PT1855677E (cg-RX-API-DMAC7.html)
RS (1) RS50807B (cg-RX-API-DMAC7.html)
RU (1) RU2407743C2 (cg-RX-API-DMAC7.html)
SI (1) SI1855677T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007017654A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039627B2 (en) 2006-11-08 2011-10-18 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
WO2011153157A2 (en) 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012135595A2 (en) 2011-04-01 2012-10-04 3M Innovative Properties Company Films including triazine-based ultraviolet absorbers
KR20160111999A (ko) 2014-01-27 2016-09-27 오스펙스 파마슈티칼스, 인코포레이티드 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
CN113413385A (zh) * 2014-02-07 2021-09-21 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
HRP20240304T1 (hr) 2015-10-30 2024-05-10 Neurocrine Biosciences, Inc. Soli valbenazin dihidroklorida i njihovi polimorfi
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
EP4400171A3 (en) * 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
KR20190108146A (ko) 2017-01-27 2019-09-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 特定のvmat2インヒビターを投与するための方法
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
JOP20200336A1 (ar) 2018-08-15 2020-12-22 Neurocrine Biosciences Inc طرق إعطاء مثبطات vmat2 معينة
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US2843591A (en) 1958-07-15 Method for preparing same
CA2058640A1 (en) * 1991-01-25 1992-07-26 Richard R. Scherschlicht Tricyclic pyridone derivative
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2770215B1 (fr) * 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2006277753B2 (en) 2011-11-10
AU2006277753A1 (en) 2007-02-15
DK1855677T3 (da) 2009-02-09
PL1855677T3 (pl) 2009-07-31
EP1855677A1 (en) 2007-11-21
ATE415968T1 (de) 2008-12-15
CA2620960A1 (en) 2007-02-15
HRP20090074T3 (en) 2009-04-30
WO2007017654A1 (en) 2007-02-15
CY1108843T1 (el) 2014-07-02
RU2008108623A (ru) 2009-09-20
ES2318771T3 (es) 2009-05-01
EP2050451B1 (en) 2011-11-23
NZ566011A (en) 2011-01-28
EP1855677B1 (en) 2008-12-03
US20110257220A1 (en) 2011-10-20
JP2009504622A (ja) 2009-02-05
RS50807B (sr) 2010-08-31
DE602006004009D1 (de) 2009-01-15
MX2008001549A (es) 2008-04-04
EP2050451A1 (en) 2009-04-22
KR20080033500A (ko) 2008-04-16
ATE534391T1 (de) 2011-12-15
RU2407743C2 (ru) 2010-12-27
HK1111083A1 (en) 2008-08-01
PT1855677E (pt) 2009-01-13

Similar Documents

Publication Publication Date Title
PT1855677E (pt) 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
TW200734311A (en) New compounds
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
IL173002A (en) Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritis
IL175762A0 (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
SI1861100T1 (sl) 3,11b-cis-dihidrotetrabenazin za zdravljenje proliferacijske bolezni ali vnetja
IL186748A0 (en) 4 - phenyl - 5 - oxo 1, 4, 5, 6, 7, 8 - hexahydroquinoline derivatives for the treatment of infertility
IL186676A0 (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
IL186831A0 (en) 4-phenyl- 5-oxo - 1,4,5,6,7,8 - hexahydroquinoline derivatives as medicaments for the treatment of infertility
IL186672A0 (en) Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
MY140538A (en) Substituted n-acyl-2-aminothiazoles
ZA200800999B (en) Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
TW200714284A (en) Novel method
GB0513835D0 (en) HIV inhibitors
ZA200803101B (en) 4-oxadiozolyl-piperidine compounds and use thereof
HK1117520A (en) Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections
WO2007006548A3 (de) Antibakterielle amid-makrozyklen vii
AP2005003270A0 (en) Composition for the treatment of humans.